-
1 Comment
Cue Biopharma, Inc is currently in a long term downtrend where the price is trading 16.9% below its 200 day moving average.
From a valuation standpoint, the stock is 91.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 111.9.
Cue Biopharma, Inc's total revenue sank by 54.7% to $475K since the same quarter in the previous year.
Its net income has dropped by 24.5% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 10.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Cue Biopharma, Inc gets an overall score of 1/5.
ISIN | US22978P1066 |
---|---|
Industry | Biotechnology |
Sector | Healthcare |
Exchange | NASDAQ |
CurrencyCode | USD |
Target Price | 10 |
---|---|
Market Cap | 151M |
Beta | 1.98 |
Dividend Yield | 0.0% |
PE Ratio | None |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CUE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024